Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
<p dir="ltr">The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the bone densitometry by bon...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513554463326208 |
|---|---|
| author | Mohamed A. Yassin (16322749) |
| author2 | Mohamed O. Abdel Rahman (16555786) Anas A. Hamad (16515247) Abdul Razzakh Poil (16555788) Mohamed T. Abdelrazek (16555791) Radwa M. Hussein (16515249) Nancy A. Kassem (16555795) Afraa M. Fadul (16555796) Sarah A. Elkourashy (16555798) Abdulqadir J. Nashwan (16328993) |
| author2_role | author author author author author author author author author |
| author_facet | Mohamed A. Yassin (16322749) Mohamed O. Abdel Rahman (16555786) Anas A. Hamad (16515247) Abdul Razzakh Poil (16555788) Mohamed T. Abdelrazek (16555791) Radwa M. Hussein (16515249) Nancy A. Kassem (16555795) Afraa M. Fadul (16555796) Sarah A. Elkourashy (16555798) Abdulqadir J. Nashwan (16328993) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamed A. Yassin (16322749) Mohamed O. Abdel Rahman (16555786) Anas A. Hamad (16515247) Abdul Razzakh Poil (16555788) Mohamed T. Abdelrazek (16555791) Radwa M. Hussein (16515249) Nancy A. Kassem (16555795) Afraa M. Fadul (16555796) Sarah A. Elkourashy (16555798) Abdulqadir J. Nashwan (16328993) |
| dc.date.none.fl_str_mv | 2020-12-18T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1097/md.0000000000023637 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Denosumab_versus_zoledronic_acid_for_patients_with_beta-thalassemia_major-induced_osteoporosis/23694777 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis beta-thalassemia major denosumab osteoporosis zoledronic acid |
| dc.title.none.fl_str_mv | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the bone densitometry by bone density (DEXA) scan as a standard of care by the radiology department, then a blood test for bone-specific alkaline phosphatase and type-1 collagen telopeptide will be measured by the chemistry laboratory.</p><p dir="ltr">Patients with B-thalassemia major induced osteoporosis, who are 18 years of age or more and willing to participate in the study will be enrolled after consenting by the primary investigator in hematology outpatient clinics. Patients with osteoporosis will receive 1 of the 2 medications; at the end of the year, DEXA scan will be done to compare the response of the 2 medications. The potential risks include drug-related side effects.</p><p dir="ltr">The outcome will be measured biochemically by measuring bone-specific alkaline phosphatase and type 1 collagen carboxy telopeptide and radiologically by DEXA scan at baseline and 1 year using <i>Z</i> score.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1097/md.0000000000023637" target="_blank">http://dx.doi.org/10.1097/md.0000000000023637</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_5f4f06a6c7c908cdf096be55aff6ece3 |
| identifier_str_mv | 10.1097/md.0000000000023637 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/23694777 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosisMohamed A. Yassin (16322749)Mohamed O. Abdel Rahman (16555786)Anas A. Hamad (16515247)Abdul Razzakh Poil (16555788)Mohamed T. Abdelrazek (16555791)Radwa M. Hussein (16515249)Nancy A. Kassem (16555795)Afraa M. Fadul (16555796)Sarah A. Elkourashy (16555798)Abdulqadir J. Nashwan (16328993)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisbeta-thalassemia majordenosumabosteoporosiszoledronic acid<p dir="ltr">The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the bone densitometry by bone density (DEXA) scan as a standard of care by the radiology department, then a blood test for bone-specific alkaline phosphatase and type-1 collagen telopeptide will be measured by the chemistry laboratory.</p><p dir="ltr">Patients with B-thalassemia major induced osteoporosis, who are 18 years of age or more and willing to participate in the study will be enrolled after consenting by the primary investigator in hematology outpatient clinics. Patients with osteoporosis will receive 1 of the 2 medications; at the end of the year, DEXA scan will be done to compare the response of the 2 medications. The potential risks include drug-related side effects.</p><p dir="ltr">The outcome will be measured biochemically by measuring bone-specific alkaline phosphatase and type 1 collagen carboxy telopeptide and radiologically by DEXA scan at baseline and 1 year using <i>Z</i> score.</p><h2>Other Information</h2><p dir="ltr">Published in: Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1097/md.0000000000023637" target="_blank">http://dx.doi.org/10.1097/md.0000000000023637</a></p>2020-12-18T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1097/md.0000000000023637https://figshare.com/articles/journal_contribution/Denosumab_versus_zoledronic_acid_for_patients_with_beta-thalassemia_major-induced_osteoporosis/23694777CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/236947772020-12-18T00:00:00Z |
| spellingShingle | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis Mohamed A. Yassin (16322749) Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis beta-thalassemia major denosumab osteoporosis zoledronic acid |
| status_str | publishedVersion |
| title | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| title_full | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| title_fullStr | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| title_full_unstemmed | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| title_short | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| title_sort | Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis |
| topic | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis beta-thalassemia major denosumab osteoporosis zoledronic acid |